Immunoglobulin E specific for Artemisia vulgaris allergens (Mugwort-specific IgE)

Patient IgE antibodies specific for Artemisia vulgaris (Mugwort) allergens are the primary mediators of Type I hypersensitivity reactions to Mugwort pollen. These antibodies bind to specific allergenic proteins, most notably Art v 1 (the major defensin-like allergen), as well as Art v 2, Art v 3 (a lipid transfer protein), and others (WHO/IUIS Allergen Nomenclature). Upon exposure to the pollen, these IgE molecules, which are typically bound to high-affinity FcεRI receptors on mast cells and basophils, cross-link with the allergens, triggering the release of inflammatory mediators like histamine and leukotrienes (PubMed: 29101900). This process leads to clinical symptoms of seasonal allergic rhinitis, conjunctivitis, and potentially asthma. In some cases, cross-reactivity with food allergens (e.g., celery, carrots, spices) leads to Mugwort-celery-spice syndrome (PubMed: 12688622). Therapeutic strategies targeting these antibodies include monoclonal antibodies like Omalizumab, which sequester free IgE, and allergen-specific immunotherapy (AIT), which seeks to desensitize the patient by modulating the immune response away from IgE production (EAACI Guidelines).

Other names

Artemisia vulgaris-specific IgEMugwort-specific IgEAnti-Art v 1 IgEAnti-Art v 2 IgEAnti-Art v 3 IgEAnti-Art v 4 IgEAnti-Art v 5 IgEAnti-Art v 6 IgE

Monoclonal antibodies like Omalizumab bind to the Fc region (specifically the Cε3 domain) of free IgE, preventing its interaction with high-affinity FcεRI receptors on mast cells and basophils. Allergen immunotherapy (AIT) induces immune tolerance by promoting a shift from Th2 to Th1/Treg responses, leading to the production of IgG4 blocking antibodies that compete with IgE for allergen binding and suppress effector cell activation.